Characteristics and in-hospital outcomes of patients undergoing balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a time-trend analysis from the Japanese nationwide registry.


Journal

Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219

Informations de publication

Date de publication:
09 2021
Historique:
received: 14 05 2021
accepted: 27 08 2021
entrez: 15 9 2021
pubmed: 16 9 2021
medline: 22 12 2021
Statut: ppublish

Résumé

Balloon pulmonary angioplasty (BPA), a novel technique initially introduced as a treatment for inoperable chronic thromboembolic pulmonary hypertension, is now increasingly being performed in a broader spectrum of patients. Here, we performed a time-trend analysis of the characteristics and in-hospital outcomes of patients who underwent BPA in Japan, using data extracted from nationwide procedure-based registration system. The Japanese Structural Heart Disease (J-SHD) registry was established and sponsored by the Japanese Association of Cardiovascular Intervention and Therapeutics and aims to provide basic statistics on the performance of structural interventions in Japan. J-SHD registers cases from approximately 200 institutions, representing more than 90% of SHD intervention-performing hospitals in the nation. We analysed the registered BPA data elements from January 2015 to December 2018. Successful BPA was defined as a session in which a physician successfully treated all targeted lesions. There were a total of 2512 BPA sessions; the number of institutions and registered sessions increased from 30 to 50 sites and from 479 to 852 sessions during the study period, respectively. The average age of the patients was 66±13 years, and 72.1% were women. In-hospital death was observed in 0.2%, and the total complications rate was 5.3%. The preoperative and postoperative mean pulmonary artery pressure were 32±11 mm Hg and 30±10 mm Hg, respectively. The number of BPA sessions increased during the study period, with an acceptable in-hospital complication rate.

Sections du résumé

BACKGROUND
Balloon pulmonary angioplasty (BPA), a novel technique initially introduced as a treatment for inoperable chronic thromboembolic pulmonary hypertension, is now increasingly being performed in a broader spectrum of patients. Here, we performed a time-trend analysis of the characteristics and in-hospital outcomes of patients who underwent BPA in Japan, using data extracted from nationwide procedure-based registration system.
METHODS
The Japanese Structural Heart Disease (J-SHD) registry was established and sponsored by the Japanese Association of Cardiovascular Intervention and Therapeutics and aims to provide basic statistics on the performance of structural interventions in Japan. J-SHD registers cases from approximately 200 institutions, representing more than 90% of SHD intervention-performing hospitals in the nation. We analysed the registered BPA data elements from January 2015 to December 2018. Successful BPA was defined as a session in which a physician successfully treated all targeted lesions.
RESULTS
There were a total of 2512 BPA sessions; the number of institutions and registered sessions increased from 30 to 50 sites and from 479 to 852 sessions during the study period, respectively. The average age of the patients was 66±13 years, and 72.1% were women. In-hospital death was observed in 0.2%, and the total complications rate was 5.3%. The preoperative and postoperative mean pulmonary artery pressure were 32±11 mm Hg and 30±10 mm Hg, respectively.
CONCLUSION
The number of BPA sessions increased during the study period, with an acceptable in-hospital complication rate.

Identifiants

pubmed: 34521747
pii: openhrt-2021-001721
doi: 10.1136/openhrt-2021-001721
pmc: PMC8442101
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Proc Am Thorac Soc. 2006 Sep;3(7):608-14
pubmed: 16963542
Eur Respir Rev. 2014 Sep;23(133):393-5
pubmed: 25176976
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Circ Cardiovasc Interv. 2012 Dec;5(6):756-62
pubmed: 23132237
Gen Thorac Cardiovasc Surg. 2011 Sep;59(9):636-67
pubmed: 22231795
Circ Cardiovasc Interv. 2012 Dec;5(6):748-55
pubmed: 23192917
J Thorac Cardiovasc Surg. 2011 Mar;141(3):702-10
pubmed: 21335128
EuroIntervention. 2016 Dec 10;12(11):e1435
pubmed: 27934612
J Cardiol. 2020 Aug;76(2):205-210
pubmed: 32402668
Circulation. 2011 Nov 1;124(18):1973-81
pubmed: 21969018
Eur Respir J. 2017 Jun 8;49(6):
pubmed: 28596435
Int J Cardiol. 2014 Dec 20;177(3):e139-41
pubmed: 25300656
Int J Cardiol. 2020 Feb 1;300:228-235
pubmed: 31813677
Diabetol Int. 2018 Mar 27;9(1):1-45
pubmed: 30603347
Circ J. 2012;76(2):485-8
pubmed: 22185711
Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65
pubmed: 22878278
Circ Cardiovasc Qual Outcomes. 2017 Nov;10(11):
pubmed: 29101270
N Engl J Med. 2013 Jul 25;369(4):319-29
pubmed: 23883377
Eur Respir J. 2019 May 18;53(5):
pubmed: 31023842
Hypertens Res. 2014 Apr;37(4):253-390
pubmed: 24705419
Heart. 2013 Oct;99(19):1415-20
pubmed: 23846611
Circulation. 2001 Jan 2;103(1):10-3
pubmed: 11136677
Cardiovasc Interv Ther. 2020 Jul;35(3):218-226
pubmed: 32440831
Pulm Circ. 2020 Jul 23;10(3):2045894020938986
pubmed: 32754307
Int J Cardiol. 2018 Dec 1;272S:69-78
pubmed: 30195840
Heart Views. 2013 Jul;14(3):106-16
pubmed: 24696755
J Atheroscler Thromb. 2013;20(6):517-23
pubmed: 23665881

Auteurs

Shun Minatsuki (S)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Mitsuyoshi Takahara (M)

Department of Diabetes Care Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

Arihiro Kiyosue (A)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Satoshi Kodera (S)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Masaru Hatano (M)

Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Jiro Ando (J)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Shun Kohsaka (S)

Department of Cardiology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan sk@keio.jp.

Hideki Ishii (H)

Department of Cardiology, Fujita Health University Bantane Hospital, Nagoya, Aichi, Japan.

Toshiro Shinke (T)

Department of Cardiology, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan.

Tetsuya Amano (T)

Department of Cardiology, Aichi Medical University, Nagakute, Aichi, Japan.

Yuji Ikari (Y)

Cardiovascular Medicine, Tokai University Hospital, Isehara, Kanagawa, Japan.

Issei Komuro (I)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH